USE IR-Spectroscopy in treatment oncology patient with bone metastases by 153 Smoxabifor
| dc.contributor.author | Grushka, Ganna | |
| dc.contributor.author | Dikiy, N. | |
| dc.contributor.author | Krasnoselskiy, Nikolai | |
| dc.contributor.author | Bereznyak, E. | |
| dc.contributor.author | Medvedeva, E. | |
| dc.date.accessioned | 2020-11-30T17:38:08Z | |
| dc.date.available | 2020-11-30T17:38:08Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Using infrared spectroscopy, we studied the character of intermolecular interactions in the samples blood plasma of oncological patients with bone metastases in the treatment of their modern β-emitter 153Sm-oxabifor. The therapeutic dose of the 153Sm-oxabifor was 1.0 mCi/kg of the patient's body weight. Analysis of the IR-spectra showed that already after the rst course of palliative radionuclide therapy there is a tendency to balance the products of free radical nature and antioxidants, which indicates the e ectiveness of the treatment. Molecular changes in the blood plasma of cancer patients with bone metastases registered using infrared spectroscopy are speci c during palliative therapy. | en_US |
| dc.identifier.citation | USE IR-Spectroscopy in treatment oncology patient with bone metastases by 153 Smoxabifor / N. P. Dikiy, N. V. Krasnoselsky, E. P. Bereznyak, A. V. Grushka, E. P. Medvedeva // Problems of atomic science and technology. – 2020. – N 5 (129). – Р. 46–51. | en_US |
| dc.identifier.issn | 1562-6016 | |
| dc.identifier.uri | https://repo.knmu.edu.ua/handle/123456789/27632 | |
| dc.language.iso | en | en_US |
| dc.publisher | Национальный научный центр Харьковский физико-технический институт | en_US |
| dc.subject | oxabifor | en_US |
| dc.subject | bone metastases | en_US |
| dc.title | USE IR-Spectroscopy in treatment oncology patient with bone metastases by 153 Smoxabifor | en_US |
| dc.type | Article | en_US |